College of Psychiatric and Neurologic Pharmacists

Title: Toward a Better Understanding of Bipolar Depression: Current Issues in Diagnosis & Treatment

Location: Baltimore Marriott Waterfront, Grand Ballroom Salon 5

Program Description
Live, interactive, case-study presentations will be conducted during the symposium that will incorporate clinical assessment and treatment decision-making experiences. Expert speakers will provide current clinical data as they discuss representative cases that occur in the practical management of bipolar depression.

Learning Objectives
Using case-based scenarios,

• Identify clinical symptomatology consistent with bipolar spectrum disorders, differentiating depressive symptoms in unipolar vs. bipolar illness.
• Recognize comorbidities that often confound accurate diagnosis of bipolar depression in adults and youth.
• Identify current treatment options for management of bipolar depression in adults and youth.
• Strategize best practices to avoid switching into mania when treating bipolar depression and to attain optimal adherence over the course of therapy.

Agenda

6:30-7:00 PM	Registration and Seating/Meal Function
7:00-7:10 PM	Welcome & Introductions: Nick Patel, PharmD, PhD
7:10-7:30 PM	Case Study: Making the Right Diagnosis: Unipolar vs. Bipolar Depression Roy H. Perlis, MD
7:30-7:50 PM	Case Study: Current Treatment Strategies for Bipolar Depression in the Real World Robert Post, MD
7:50-8:10 PM	Case Study: Making the Right Diagnosis: The Sad, Irritable Youth Robert Kowatch, MD
8:10-8:30 PM	Panel Discussion/Q&A

Faculty:

• Nick C. Patel, PharmD, PhD (Program Chair/Moderator)
  Assistant Professor
  Department of Pharmacy Practice, College of Pharmacy
  Department of Psychiatry, College of Medicine
  University of Cincinnati
  Cincinnati, OH
• Roy H. Perlis, MD
  Director, Psychopharmacology Consultation Service
  Massachusetts General Hospital Mood & Anxiety Disorder Institute
  Assistant Professor of Psychiatry
  Harvard Medical School
  Boston, MA
• Robert A. Kowatch, MD
  Director, Pediatric Mood Disorder Center
  Cincinnati Childrens Hospital Medical Center
  Professor of Psychiatry and Pediatrics
  University of Cincinnati
  Cincinnati, OH
• Robert M. Post, MD
  Special Volunteer
  National Institute of Mental Health
  Bethesda, MD

Accreditation:
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE # 245-000-06-006-L01 and will award 1.5 contact hours (0.15 CEUs) of continuing education credit. CEC complies with the Criteria for Quality for continuing pharmacy education programming. Statements of credit will be issued to those participants attending the program and completing a CE request form and will be mailed within 10 business days.

Registration:
Please visit www.ceconcepts.net for registration information.

Commercial Supporter:
This program is supported by an independent educational grant from AstraZeneca.

Title: Management of Major Depressive Disorders in the 21st Century: Current and Novel Treatment Options

Location: Baltimore Marriott Waterfront, Grand Ballroom 5

Program Description:
Major depressive disorder (MDD) is a chronic and debilitating illness that affects 23 million Americans each year. Comorbid medical illness often increases the risk and severity of depression, complicating both the treatment and diagnosis of MDD. Despite the high prevalence of MDD and the availability of treatment options, it remains underrecognized and undertreated. Among patients who do receive treatment, an overwhelming majority does not achieve sustained remission, and more than 20% of all patients are resistant to initial pharmacotherapy, meeting the DSM-IV criteria for chronic depression. Monoamine oxidase inhibitors (MAOIs) have long been demonstrated to be highly effective at treating MDD but are rarely prescribed because of safety concerns. As a result of innovations in drug delivery systems, MAOIs can now be administered using a transdermal system, providing effective treatment while increasing safety and tolerability. This symposium will explore various classes of pharmacologic agents available for the management of MDD and will review strategies that have the potential to improve the overall effectiveness of treatment.


Educational Objectives:
After participating in this activity, participants should be better able to:

1. Assess the risks associated with comorbid psychiatric and medical illnesses for patients with depression
2. Critically evaluate tolerability and efficacy data pertaining to long-term pharmacotherapy for major depressive disorder
3. Discuss novel strategies and delivery mechanisms for pharmacologic agents used in the management of depression

Agenda:

12:15 pm 12:45 pm	Registration and Lunch
12:45 pm 12:50 pm	Welcome and Introductions Steven C. Stoner, PharmD, BCPP
12:50 pm 1:10 pm	Complications of Depression: Comorbid Medical Illnesses and Psychiatric Disorders J. Craig Nelson, MD
1:10 pm 1:30 pm	Evidenced-based Strategies for Treating Depression J. Alexander Bodkin, MD
1:30 pm 1:50 pm	Improving the Efficacy of Antidepressant Pharmacotherapy: Novel Targets and Delivery Mechanisms Steven C. Stoner, PharmD, BCPP
1:50 pm 2:10 pm	Panel Discussion Moderated by Steven C. Stoner, PharmD, BCPP
2:10 pm 2:15 pm	Closing Remarks Steven C. Stoner, PharmD, BCPP

Activity Chairperson:
Steven C. Stoner, PharmD, BCPP
Clinical Associate Professor
University of Missouri-Kansas City Schools of Pharmacy and Medicine
Northwest Missouri Psychiatric Rehabilitation Center
Kansas City, Missouri

Faculty:

• J. Alexander Bodkin, MD
  Chief, Clinical Psychopharmacology Research Program
  McLean Hospital
  Belmont, Massachusetts

• J. Craig Nelson, MD
  Leon J. Epstein Professor of Psychiatry
  Director of Geriatric Psychiatry
  University of California San Francisco
  San Francisco, California

Accreditation Statement:
SciMed is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation:
SciMed designates this educational activity (for 1.5 contact hour(s) (0.15 CEUs). No partial credit will be awarded.

Registration:
To register, please send your contact information to Julie Suesserman at jsuesserman@scimedny.com.

Commercial Supporter: This program is supported by an independent educational grant from Bristol-Myers Squibb Company.

Title: Rx for Success in Bipolar Mania: Novel Agents and Clinical Implications

Location: Baltimore Marriott Waterfront, Grand Ballroom Salon 5

Program Description
Over 35% of bipolar patients are symptomatic for a decade before receiving appropriate treatment. Join us to discover new data about bipolar disorder and novel mood stabilizers in an interactive, game show format. Use your skills to compete with your colleagues in an audience response activity for knowledge and rewards.

Learning Objectives
At the conclusion of this program, you will be able to:

• Illustrate the clinical presentation of manic symptoms to differentiate from other psychiatric conditions.
• Outline treatment algorithms in current bipolar mania clinical guidelines and apply an optimal treatment approach for real-world patients.
• Appropriately select mood stabilizers to maximize safety and tolerability.
• Apply pharmacokinetic properties of novel mood stabilizers to appropriately dose and monitor these agents.

Agenda

6:30-7:00 PM	Registration and Seating/Meal Function
7:00-7:05 PM	Welcome & Introductions
7:05-8:25 PM	Rx for Success in Bipolar Mania: Novel Agents and Clinical Implications Bipolar Disorder Update: Implications for Psychiatric Pharmacists Update on Bipolar Guidelines and Therapies Novel Mood Stabilizers: Whats New in Formulations?
8:25-8:45 PM	Educational Game Show
8:45-9:00 PM	Panel Discussion/Q&A

Moderator and Emcee:
Roger Sommi, PharmD, BCPP, FCCP
Professor of Pharmacy Practice and Psychiatry
University of Missouri Kansas City
School of Pharmacy
Kansas City, Missouri

Faculty:

• Matthew Fuller, PharmD, BCPS, BCPP, FASHP
  Clinical Pharmacy Specialist in Psychiatry
  VA Medical Center
  Brecksville, Ohio
• Robert Hirschfeld, MD
  Professor and Chair
  University of Texas Medical Branch
  Department of Psychiatry and Behavioral Sciences
  Galveston, Texas
• Robert M. Post, MD
  Special Volunteer
  National Institute of Mental Health
  Bethesda, Maryland
• Karen Wagner, MD, PhD
  Professor and Vice Chair
  University of Texas Medical Branch
  Department of Psychiatry and Behavioral Sciences
  Galveston, Texas

Accreditation:
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE # 245-000-06-007-L01 and will award 2.0 contact hours (0.20 CEUs) of continuing education credit. CEC complies with the Criteria for Quality for continuing pharmacy education programming. Statements of credit will be issued to those participants attending the program and completing a CE request form and will be mailed within 10 business days.

Registration:
Please visit www.ceconcepts.net for registration information.

Commercial Supporter:
This program is supported by an independent educational grant from Shire US Inc.

Title: Management of Psychotic Disorders: Transitioning From Acute to Maintenance Treatment

Location: Baltimore Marriott Waterfront, Grand Ballroom 5

Program Description:
Atypical antipsychotics have become the mainstay of therapy for the management of psychotic disorders, including bipolar disorder and schizophrenia. Although often grouped as a class, these agents have distinct pharmacologic profiles that may result in meaningful differences in their clinical effects. Atypical antipsychotics have a differential propensity for causing sedation, hyperprolactinemia and its sequelae, as well as metabolic abnormalities such as weight gain, glucose intolerance, diabetes, and dyslipidemia. These adverse effects may, in turn, have an adverse impact on adherence to therapy and compromise long-term therapeutic outcomes. Effective management of psychotic disorders requires consideration of the full spectrum of effects of the therapeutic intervention and the long-term implications of therapy. This symposium will review the mechanistic evolution of antipsychotic agents and will examine the pharmacologic basis for variations in their clinical profiles. Strategies for achieving optimal therapeutic outcomes in both the acute and maintenance settings will also be discussed.

Learning Objectives:
After participating in this activity, participants should be better able to:

1. Discuss the pharmacologic evolution of antipsychotic agents
2. Describe the differential adverse effects profiles of antipsychotic agents and the potential impact of these adverse effects on adherence to therapy and achieving desired therapeutic outcomes
3. Evaluate the latest clinical trial data assessing the role of atypical antipsychotics in the management of various psychotic disorders, including bipolar disorder and schizophrenia
4. Choose an appropriate atypical antipsychotic based on patient-specific needs to achieve desired outcomes in both the acute and maintenance settings

Agenda:

12:45 pm 1:15 pm	Registration and Lunch
1:15 pm 1:20 pm	Opening Remarks
1:20 pm 1:40 pm	Differential Pharmacologic Profiles of Atypical Antipsychotics and Their Implications for Treatment Outcomes
1:40 pm 2:00 pm	Management of Acute Psychosis: From Acute Care to Maintenance Therapy
2:00 pm 2:20 pm	An Evidence-based Approach to Long-term Patient Outcomes in Patients With Psychiatric Disorders
2:20 pm 2:40 pm	Panel Discussion
2:40 pm 2:45 pm	Closing Remarks

Activity Chairperson:
Raymond C. Love, PharmD, BCPP, FASHP
Professor and Vice-Chair
Department of Pharmacy Practice and Science
School of Pharmacy
Associate Professor
Department of Psychiatry
University of Maryland
Baltimore, Maryland

Accreditation Statement:
SciMed is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation:
SciMed designates this educational activity for 1.5 contact hours (0.15 CEUs). No partial credit will be awarded.

Registration:
To register, please send your contact information to Rebecca Ryen at rryen@scimedny.com.

Commercial Supporter:
This program is supported by an independent educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Title: Applications of Pharmacogenomics in CNS

Location: Baltimore Marriott Waterfront, Grand 7-10

Program Description:
Pharmacogenomics has played a role in various aspects of medicine since the beginning of time, through effects on disease presence, drug activity, and pharmacokinetics. However, the presence of pharmacogenomics has drastically increased during the last decade. Now it is possible to more readily identify gene mutations, better predict drug actions with respect to efficacy or adverse events, and to apply this in clinical settings. This symposium will review the role of pharmacogenomics in the central nervous system, discuss recent studies that have demonstrated the usefulness of pharmacogenomics, and focus on the means by which you can incorporate the information into patient management.

Learning Objectives:

• Discuss how pharmacogenomics has demonstrated usefulness in different areas of medicine.
• Review the reasons that psychiatry is an ideal environment for the science of pharmacogenomics to be employed in patient care
• Discuss the latest tests used in the area of pharmacogenomics and what value it has to the physician
• Understand current pharmacogenomic guidelines in psychiatry.
• Discuss how CYP2D6 genotyping may help personalize psychiatry, in particular risperidone dosing.
• Discuss the challenges that exist with studies that demonstrate genotyping use in psychiatry clinical practice
• State the general circumstances that make patient-specific pharmacogenomic data useful in the clinical setting.
• Discuss the requirements of the clinical pharmacist for applying pharmacogenomic data to patient care.
• Discuss the potential advantages and disadvantages of various technology platforms for generating genotype data.

Agenda:

6:30-7:00 AM	Breakfast
7:00-7:10 AM	Welcome and Introduction: A Brief History of Pharmacogenomics
7:10 - 7:40 AM	Pharmacogenomics - A Concept Whose Time Has Come
7:40 - 8:10 AM	Review of pharmacogenomic studies of CNS drugs with focus on CYP2D6 and CYP2C19
8:10 - 8:40 AM	Future Directions for Application of Genetic Technology in Clinical Pharmacy Practice
8:40 - 9:00 AM	Panel Discussion

Program Chair:
Gary M. Levin, Pharm.D., BCPP, FCCP
Professor and Chairman,
Department of Pharmacy Practice
Nova Southeastern University
College of Pharmacy

Faculty:

• Keith Candiotti, M.D., Associate Professor of Anesthesiology and Internal Medicine
  Director of Clinical Research, Chief, Division of Perioperative Medicine
  University of Miami Department of Anesthesiology
  Perioperative Medicine and Pain Management
• Jose de Leon, M.D., Associate Professor
  Department of Psychiatry, College of Medicine and Pharmacy Practice & Sciences, College of Pharmacy
  University of Kentucky
  Medical Director, University of Kentucky Mental Health Research Center at Eastern State Hospital
  Lexington, KY
• C. Lindsay DeVane, Pharm.D., BCPP, FCCP, Professor and Vice Chair for Research
  Department of Psychiatry & Behavioral Sciences
  Medical University of South Carolina

Accreditation:
The College of Psychiatric & Neurologic Pharmacists (CPNP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE # 284-000-06-006-L01 and will award 2.0 contact hours (0.20 CEUs) of continuing education credit. CPNP complies with the Criteria for Quality for continuing education programming. Statements of credit will be issued to those participants attending the program via the CPNP website within 1 month following the program.

Registration:
Three ways to register. Include name/credentials/address/phone/fax/email/business affiliation:

• Fax registration information to: 402-476-1677
• Telephone registration: 402-476-1677
• Email: jolson@cpnp.org

Commercial Supporter: This program is supported by an independent educational grant from Roche Molecular Systems, Inc.